Stockholm Stock Exchange | Mid Cap
Biogaia
+4.27%
Latest
+4.27%
3 months
SEBHandelsbankenCarnegieHandelsbanken Capital Markets

Price Targets For Biogaia

AnalystPrice TargetDateUpside
SEB110 SEKOct 23
+4.27%
Handelsbanken175 SEKJun 20
Carnegie150 SEKMay 8
Handelsbanken Capital Markets130 SEKFeb -23

About The Company

Biogaia AB is a Swedish biotechnology company that develops and sells probiotic products. Biogaia has been developed from research findings on the lactic acid bacterium Limosilactobacillus reuteri and the substance reuterin, which was carried out by Walter Dobrogosz and Sven Lindgren in the 1980s.
Wikipedia